Link to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-18 05:04:472019-09-19 05:15:38New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
Link to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-17 04:56:162019-09-19 05:17:33AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
Link to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-12 04:54:002019-09-19 04:55:22Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye Marks the fourth research grant Destiny […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-10 04:40:352019-09-12 04:42:56Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections
Link to Full Article Valencia, Calif., USA, and Melbourne, Australia, 6 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-09-05 04:59:432019-09-06 05:04:16AVITA Medical Added to the S&P/ASX 300 Index
Link to Full Article San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-08-23 04:56:252019-09-06 04:58:01Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
Melbourne, Australia – August 22, 2019: Adherium Limited (“Adherium” or the “Company”) (ASX: ADR) is pleased to announce it has received commitments from existing significant shareholders and new investors to subscribe for $1.8m of secured notes to be issued by the Company (2019 Notes). Subscribers to the 2019 Notes include One Funds Management Limited as […]
Link to Full Article Adaptix have just won an STFC Bridging for Innovators (B4i) grant worth over £40,000 for work with the prestigious Ultra High Vacuum Group at STFC Daresbury – to develop cleaning processes for the manufacture of Adaptix’s patented Flat Panel X-ray Source. Bridging for Innovators (B4I) is an Industrial Strategy Challenge Fund (ISCF) programme run […]
Melbourne, Australia – August 20, 2019: Leading respiratory medical device company Adherium (ASX:ADR) has unveiled its new strategic data-based initiative with Summatix Pty Ltd, with the objective of enabling clinicians globally to enhance their care of patients with asthma and chronic obstructive pulmonary disease (COPD). This follows Adherium’s post-reorganisation business model of enhancing its sensor […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-08-20 02:36:062019-08-22 02:42:50Adherium and Summatix announce strategic initiative to enhance Hailie™ Solution’s Digital Platform Impact
Link to Full Article MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced second quarter results and provided a corporate and clinical update. Key Second Quarter and Subsequent Period Highlights: Successfully completed […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-08-14 04:44:572019-08-15 04:46:07Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
New Data Published in Aesthetic Plastic Surgery Explores the Use of the RECELL System in Combination with Dermabrasion to Treat Acne Scars
/in Avita MedicalLink to Full Article Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions Valencia, Calif., USA, and Melbourne, Australia, 19 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the healing properties of a […]
AVITA Medical Receives U.S. FDA Investigational Device Exemption Approval of Pivotal Study Evaluating RECELL System for Soft Tissue Reconstruction
/in Avita MedicalLink to Full Article First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months Valencia, Calif., USA, and Melbourne, Australia, 17 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization […]
Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa
/in Armata PharmaceuticalsLink to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]
Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the company”) Destiny Pharma awarded grant to fund a research collaboration with the University of Sheffield targeting ophthalmic bacterial and fungal infections Collaboration to investigate antimicrobial candidates from the company’s XF drug platform against microbial infections of the eye Marks the fourth research grant Destiny […]
AVITA Medical Added to the S&P/ASX 300 Index
/in Avita MedicalLink to Full Article Valencia, Calif., USA, and Melbourne, Australia, 6 September 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 […]
Adherium and Vitalus Health Launch Commercial Program to Support Patients with Asthma and COPD
/in AdheriumLink to Full Article San Mateo, CA – August 23, 2018: Adherium (ASX:ADR) a digital health platform focused on improving medication adherence and patient outcomes, and Vitalus Health, a leading provider of comprehensive health and wellness solutions that focus on pulmonary disease management, today announced a broadened strategic program encompassing Adherium’s Hailie™ solution. With the expansion of […]
Adherium announces $1.8m secured notes financing; ASX waiver granted
/in AdheriumMelbourne, Australia – August 22, 2019: Adherium Limited (“Adherium” or the “Company”) (ASX: ADR) is pleased to announce it has received commitments from existing significant shareholders and new investors to subscribe for $1.8m of secured notes to be issued by the Company (2019 Notes). Subscribers to the 2019 Notes include One Funds Management Limited as […]
Adaptix secures STFC Bridging for Innovators grant…
/in AdaptixLink to Full Article Adaptix have just won an STFC Bridging for Innovators (B4i) grant worth over £40,000 for work with the prestigious Ultra High Vacuum Group at STFC Daresbury – to develop cleaning processes for the manufacture of Adaptix’s patented Flat Panel X-ray Source. Bridging for Innovators (B4I) is an Industrial Strategy Challenge Fund (ISCF) programme run […]
Adherium and Summatix announce strategic initiative to enhance Hailie™ Solution’s Digital Platform Impact
/in AdheriumMelbourne, Australia – August 20, 2019: Leading respiratory medical device company Adherium (ASX:ADR) has unveiled its new strategic data-based initiative with Summatix Pty Ltd, with the objective of enabling clinicians globally to enhance their care of patients with asthma and chronic obstructive pulmonary disease (COPD). This follows Adherium’s post-reorganisation business model of enhancing its sensor […]
Armata Pharmaceuticals Announces Second Quarter Results and Provides Corporate and Clinical Update
/in Armata PharmaceuticalsLink to Full Article MARINA DEL REY, Calif., Aug. 14, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced second quarter results and provided a corporate and clinical update. Key Second Quarter and Subsequent Period Highlights: Successfully completed […]